Arena Shares Full Data Supporting Etrasimod’s Long-term Safety and Efficacy

Arena Shares Full Data Supporting Etrasimod’s Long-term Safety and Efficacy
Arena Pharmaceuticals announced full long-term results of its OASIS extension study, confirming that once-daily oral etrasimod leads to sustained clinical responses and favorable safety for up to 46 weeks in patients with moderate to severe ulcerative colitis (UC). Arena is currently recruiting patients for its Phase 3 ELEVATE UC 52 trial (NCT03945188) testing etrasimod. The findings were shared at United European Gastroenterology (UEG) Week, Oct.19-23 in Barcelona, Spain, in a poster titled "Long-term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study". "We are delighted to see that most patients who achieved clinical response, clinical remission, or endoscopic improvement at week 12 experienced sustained or improved effects up to week 46 with etrasimod 2 mg in the open-label extension of our Phase 2 OASIS trial.  Etrasimod also demonstrated a favorable safety profile, consistent with safety findings reported in the double-blind portion of OASIS," Preston Klassen, Arena's executive vice president, head of research and development, said in a press release. Etrasimod (APD334) is an investigational treatment under development by Arena for immune-mediated and inflammatory diseases such as UC, Crohn’s disease, and atopic dermatitis. It is an oral, selective modulator of sphingosine 1-phosphate (S1P) receptors, designed to retain immune cells, specifically certain lymphocytes, inside lymph nodes so that fewer of them are available to enter the blood and contribute to tissue inflammation and damage. Arena's open-label extension study (NCT02536404) evaluated for an additional 34 weeks the safety and efficacy of etrasimod in adults with moderate to severe active UC who completed induction therapy i
Subscribe or to access all post and page content.